News

Mallinckrodt Completes Enrollment in Phase 4 Trial Testing Acthar Gel in SLE Patients

Mallinckrodt Pharmaceuticals has completed enrollment for its Phase 4 clinical trial evaluating the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) in patients with persistently active systemic lupus erythematosus (SLE). The company expects the first results to be available by early 2020. “I am delighted that enrollment is completed, and look forward…

LRA Funds Research Projects to Find New Therapies for Lupus

The Lupus Research Alliance (LRA) has funded a series of research projects, ongoing worldwide, aimed at seeking new therapies for people with lupus. The award recipients presented their findings at the recent 13th International Congress on Systematic Lupus Erythematosus (LUPUS 2019), in San Francisco, California. One of the…

Lupus 2019 Conference Speaker Emphasizes the Patient’s Voice

As part of The Patient Voice segment of the 13th International Congress on Systemic Lupus Erythematosus, prominent lupus advocate Kathleen Arntsen discussed the importance of making sure those living with the disease are heard. Known informally as Lupus 2019, the April 5-8 meeting in San Francisco, California, was…